Compare NRIX & KN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NRIX | KN |
|---|---|---|
| Founded | 2009 | 1946 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Consumer Electronics/Appliances |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 2020 | 2013 |
| Metric | NRIX | KN |
|---|---|---|
| Price | $15.88 | $28.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 3 |
| Target Price | ★ $29.46 | $22.33 |
| AVG Volume (30 Days) | ★ 844.9K | 689.4K |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 118.94 |
| EPS | N/A | ★ 0.50 |
| Revenue | $76,987,000.00 | ★ $593,200,000.00 |
| Revenue This Year | N/A | $9.40 |
| Revenue Next Year | $29.30 | $6.98 |
| P/E Ratio | ★ N/A | $54.97 |
| Revenue Growth | ★ 99.31 | 7.17 |
| 52 Week Low | $8.18 | $12.19 |
| 52 Week High | $22.50 | $27.73 |
| Indicator | NRIX | KN |
|---|---|---|
| Relative Strength Index (RSI) | 42.26 | 73.49 |
| Support Level | $15.62 | $23.81 |
| Resistance Level | $19.98 | N/A |
| Average True Range (ATR) | 0.78 | 0.94 |
| MACD | -0.03 | 0.10 |
| Stochastic Oscillator | 36.46 | 98.68 |
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
Knowles Corp is engaged in the manufacturing of micro-acoustic microphones and balanced armature speakers, audio solutions, high-performance capacitors, and radio frequency filtering products. It operates in two segments; the Precision Devices segment specializes in the design and delivery of high-performance capacitor products and RF solutions; and Medtech & Specialty Audio segment designs and manufactures microphones and balanced armature speakers used in applications. The majority of its revenue comes from the Precision Devices. Geographically, it operates in United States, Asia, Other Americas, Europe and Others, out of which United States generates maximum revenue.